ArticleAngewandte Chemie (International ed. in English)2026
Dynamic Binder Exchange Improves Protein Labeling Efficiency in DNA-PAINT up to 15-Fold.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Dynamic Binder Exchange (DyBE) enhances DNA-PAINT (Point Accumulation for Imaging in Nanoscale Topography) super-resolution microscopy by exploiting transient, reversible binder-target interactions. DyBE uses DNA-conjugated binders such as nanobodies as both targeting and docking moieties, integrating their characteristic higher off-rates with DNA-PAINT blinking to efficiently sample target sites. This dual-kinetic scheme increases labeling efficiency up to 15-fold, enabling sensitive detection of targets previously inaccessible due to limitations of high-off-rate binders. Using DyBE, the study reveals pre-existing HER2 homodimers and ligand-induced EGFR-HER2 heterodimers at single-protein resolution with high fidelity. DyBE expands the usable binder repertoire, advancing spatial proteomics and enabling mechanistic drug studies of receptor organization and signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.